论文部分内容阅读
采用定量ＥＬＩＳＡ法检测了４６例慢性支气管炎及３８例肺癌患者血浆ＳＥ－ＳＬＴ含量，结果分别为５１．２３±１２．０９μｇ／Ｌ，５５．８６±１３．３１μｇ／Ｌ，两组比较无显著性差异（Ｐ＞０．０５），而与正常对照组比较均明显升高（Ｐ＜０．０１）。慢性支气管炎急性加重期与缓解期、肺癌Ⅲ～Ⅳ期与Ⅱ期比较ＳＥ－ＳＬＴ含量有非常显著差异（Ｐ＜０．０１），经治疗后则有不同程度下降。提示慢性支气管炎及肺癌患者内皮细胞Ｅ－ＳＬＴ表达增强，其含量变化与病情严重程度密切相关，可作为疗效观察、肿瘤转移、预后评估的参考指标；但对这两种疾病的鉴别诊断无特异性。
Quantitative ELISA was used to detect the serum levels of SE-SLT in 46 patients with chronic bronchitis and 38 patients with lung cancer. The results were 51.23 ± 12.09μg / L and 55.86 ± 13.31μg / L, respectively, with no significant difference between the two groups (P> 0.05), but significantly higher than that of the normal control group (P <0.01). There was a significant difference (P <0.01) in the content of SE-SLT between stage Ⅲ ~ Ⅳ and stage Ⅱ in patients with acute exacerbation and remission of chronic bronchitis, and then decreased to some extent after treatment. It suggests that the expression of E-SLT in endothelial cells of patients with chronic bronchitis and lung cancer is increased, and the content of E-SLT is closely related to the severity of the disease, which can be used as a reference index for the observation of efficacy, tumor metastasis and prognosis evaluation. However, the differential diagnosis of these two diseases is not specific Sex.